Table 1.
Patient, disease and therapy characteristics
| Demographics | Lymph node characteristics | |||||
|---|---|---|---|---|---|---|
| Median age (yrs, IQR) | 65 (51–74) | n | % | |||
| n | % | Nodal basin evaluated | ||||
| Sex | Head & neck | 38 | 18% | |||
| Female | 79 | 37% | Axilla | 108 | 50% | |
| Male | 136 | 63% | Inguinal | 69 | 32% | |
| Race | - | SLNB procedure | ||||
| White | 190 | 88% | Only SLN removed | 189 | 88% | |
| Hispanic | 20 | 9% | Additional LN removed | 26 | 12% | |
| Black | 1 | 0% | Nodal disease location | |||
| Asian | 2 | 1% | Extracapsular extension | 21 | 10% | |
| Other | 2 | 1% | Subcapsular | 190 | 88% | |
|
|
||||||
| Primary tumor characteristics | Intraparenchymal | 126 | 59% | |||
|
|
||||||
| Median Breslow depth (mm, IQR) | 2.4 (1.3–4.4) | Intravascular | 11 | 5% | ||
| n | % | Median number of lymph nodes removed | ||||
| Primary site | - | Total (IQR) | 2 (2–4) | |||
| Head & neck | 35 | 16% | Sentinel (IQR) | 2 (1.5–3) | ||
| Trunk | 75 | 35% | Median number of lymph nodes positive | |||
| Upper extremity | 50 | 23% | Total (IQR) | 1 (1–2) | ||
| Lower extermity | 55 | 26% | Sentinel (IQR) | 1 (1–2) | ||
| Histology | - | Median largest nodal deposit (mm, IQR) | 1.05 (<0.1–3) | |||
|
|
||||||
| Lentigo maligna | 8 | 4% | Adjuvant therapy | |||
|
|
||||||
| Nodular | 47 | 22% | n | % | ||
| Superficial | 125 | 58% | Immunotherapy | 95 | 44% | |
| Acral | 25 | 12% | Nivolumab | 87 | 40% | |
| Not specified | 10 | 5% | Pembrolizumab | 4 | 2% | |
| Pathologic features | - | Ipilimumab | 4 | 2% | ||
| Satellitosis | 29 | 13% | Dabrafenib + Trametinib | 7 | 3% | |
| PNI | 36 | 17% | Radiation therapy | 17 | 8% | |
| LVI | 75 | 35% | To primary tumor | 12 | 6% | |
| Ulceration | 86 | 40% | To draining nodal basin | 9 | 4% | |
|
|
||||||
| >1 mitosis/mm2 | 175 | 81% | ||||
| Mutational Status | 166 | 77% | ||||
| n | % tested | |||||
| BRAF | 79 | 37% | ||||
| NRAS | 29 | 13% | ||||
| cKit | 6 | 3% | ||||
| Other | 35 | 16% | ||||
| None detected | 15 | 7% | ||||
| Not evaluated | 49 | 23% | ||||
Abbreviations: IQR, interquartile range; LN, lymph node; LVI, lymphovascular invasion; PNI, perineural invasion; yrs, years RT, radiation therapy; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; sys tx, systemic therapy.